市場調查報告書
商品編碼
1576951
癌症放射治療設備 - 市場考察,競爭情形,市場預測(2030年)Radiotherapy/Radiation Oncology Devices - Market Insights, Competitive Landscape, and Market Forecast -2030 |
2024年至2030年的預測期內,全球癌症放射治療設備市場規模預計將以7.78%的複合年增長率成長。由於各類癌症患者數量的增加、市場參與者推出創新產品組合以及人們對早期檢測的認識不斷增強,該市場正在經歷顯著增長,預計在 2024-2030 年預測期內將有所增加。將成為加速整體市場成長的因素。
癌症放射治療設備市場動態
根據世界衛生組織(WHO)2024年提供的數據,國際癌症研究機構(IARC)表示,2022年全球新增癌症病例達2,000萬例。根據相同數據,在新登記的癌症患者中,肺癌是最常見的癌症,佔全球新患者的250萬人。其次是乳癌(230 萬)、大腸癌(190 萬)和胃癌(97 萬)。
全球癌症觀察站(2024)估計,到2030年,全球新增癌症患者數將達到2,000萬至2,410萬。根據統計,亞洲有9,826,539人,歐洲有4,471,422人,拉丁美洲和加勒比海地區有1,551,060人,非洲有1,185,216人。
越來越多的患者被診斷出患有各種癌症,迫使衛生系統實施先進的放射治療技術,以提供有效的治療選擇。患者數量的增加正在推動對放射腫瘤學基礎設施和創新設備的進一步投資,從而提振市場。
市場主要參與者增加的產品開發活動預計將促使癌症放射治療設備的市場成長。例如,2024年5月,GE HealthCare在2024年歐洲治療放射學和腫瘤學會(ESTRO)上宣布了其新的Revolution RT放射治療CT系統。據供應商稱,新系統採用大口徑 CT 平台設計,還包括與 Spectronic MRI Planner 介接的人工智慧增強版智慧放射治療 (iRT) 平台。
因此,上述所有因素的交互作用預計將在 2024-2030 年預測期內推動癌症放射治療設備市場的發展。
然而,與輻射和替代治療的可用性相關的風險因素可能會限制癌症放射治療設備市場的成長。
癌症放療設備市場區隔分析
在癌症放射治療設備市場類型領域,立體定位高級電子/鈷 60 線性加速器的伽瑪刀子類別預計將在 2023 年佔據重要的收入佔有率。這是因為伽瑪刀應用廣泛,具有多種益處,可以增強對不同類型慢性疾病的管理。
伽瑪刀是一種用多束輻射束從不同角度照射大腦特定部位的技術。每束光束都太弱,無法損壞健康組織,因此它會自行通過,造成的傷害很小。伽瑪刀還可以提供大劑量的輻射,對周圍健康的組織和結構沒有或很少造成損害,從而減少出血、感染和腦脊髓液漏等併發症。另一個優點是它不需要全身麻醉,因此沒有相關的潛在副作用,只需要一次治療。
此外,多家市場公司擁有強大的產品組合,領先的公司如Leksell、GammaKnife(R) Icon(TM)、Leksell Gamma Knife(R) Lightning、Leksell Gamma Knife(R) 我們提供廣泛的伽瑪刀產品,包括 Perfexion(TM)。
因此,伽瑪刀的廣泛應用和各種優勢提高了其性能和易用性,預計這將對2024-2030年預測期內的整體癌症放射治療設備市場成長產生重大影響。本報告提供全球癌症放射治療設備市場相關調查分析,提供各地區市場規模與預測,過去3年的產品/技術開發,市場主要企業,未來的機會等資訊。
Radiotherapy/Radiation Oncology Devices Market by Type (External Beam Radiation Therapy [Linear Accelerators (Linac), Stereotactic Advanced Electron/Cobalt-60 Linear Accelerators [Gamma Knife, CyberKnife, and TomoTherapy], Proton Therapy, Cyclotron, Synchrotron, and Others], and Internal Beam Radiotherapy/Brachytherapy), Technology (External Beam Radiation Therapy [Image-Guided Radiotherapy (IGRT), Intensity Modulated Radiotherapy (IMRT), Stereotactic Technology, Proton Beam Therapy, 3D Conformal Radiotherapy (3D CRT), and Others] and Internal Beam Radiotherapy/Brachytherapy [Low-Dose Rate Brachytherapy and High-Dose Rate Brachytherapy], Application (External Beam Radiation Therapy [Prostate Cancer, Breast Cancer, Lung Cancer, Head and Neck Cancer, Colorectal Cancer, and Others] and Internal Beam Radiation Therapy [Prostate Cancer, Gynecological Cancer, Breast Cancer, Cervical Cancer, Penile Cancer, and Others], End-User (Hospitals, Independent Radiotherapy Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to advance at a substantial CAGR forecast till 2030 owing to the increasing instances of cancer and the rising product developmental activities worldwide
The radiotherapy/radiation oncology devices market is projected to grow at a 7.78% CAGR during the forecast period from 2024 to 2030. The radiotherapy/radiation oncology devices market is growing significantly due to the increasing cases of different types of cancers among the population, the introduction of innovative product portfolios by market players, and the growing awareness for early detection are factors that are expected to escalate the overall growth of the radiotherapy/radiation oncology devices market during the forecast period from 2024 to 2030.
Radiotherapy/Radiation Oncology Devices Market Dynamics:
According to data provided by the World Health Organization in 2024, the International Agency for Research on Cancer (IARC) stated that 20 million new instances of cancer were registered in 2022 globally. As per the same source, lung cancer accounted for 2.5 million new cases globally, of all the registered new cancer cases, making it the most common cancer. Next in order of incidence was breast cancer with 2.3 million cases, colon cancer with 1.9 million cases, and stomach cancer with 0.97 million cases globally.
The Global Cancer Observatory (2024), estimated that the new instances of cancer globally would reach from 20 million to 24.1 million by the year 2030. It stated that Asia accounted for 9,826,539 cancer cases, Europe accounted for 4,471,422 cancer cases, LAC accounted for 1,551,060 cancer cases, and Africa accounted for 1,185,216 cancer cases.
As more patients are diagnosed with various cancers, healthcare systems are compelled to adopt advanced radiotherapy technologies to provide effective treatment options. This growing patient population is further driving investments in radiation oncology infrastructure and innovative devices and thereby boosting the market for same.
Increased product developmental activities by market key players is slated to witness market growth for radiotherapy/radiation oncology devices. For example, in May 2024, GE HealthCare unveiled its new Revolution RT radiation therapy CT system at the European Society for Therapeutic Radiology and Oncology (ESTRO) 2024. The new system was designed with a wide-bore CT platform and includes an updated AI-enhanced version of the Intelligent Radiation Therapy (iRT) platform, which interfaces with the Spectronic MRI Planner, according to the vendor.
Hence, the interplay of all the above-mentioned factors are expected to drive the market for radiotherapy/radiation oncology devices market during the given forecast period from 2024 to 2030.
However, risk factors associated with radiation, and the availability of alternative therapies, among others may restrict the market growth of radiotherapy/radiation oncology devices.
Radiotherapy/Radiation Oncology Devices Market Segment Analysis:
Radiotherapy/Radiation Oncology Devices Market by Type (External Beam Radiation Therapy [Linear Accelerators (Linac), Stereotactic Advanced Electron/Cobalt-60 Linear Accelerators [Gamma Knife, CyberKnife, and TomoTherapy], Proton Therapy, Cyclotron, Synchrotron, and Others], and Internal Beam Radiotherapy/Brachytherapy), Technology (External Beam Radiation Therapy [Image-Guided Radiotherapy (IGRT), Intensity Modulated Radiotherapy (IMRT), Stereotactic Technology, Proton Beam Therapy, 3D Conformal Radiotherapy (3D CRT), and Others] and Internal Beam Radiotherapy/Brachytherapy [Low-Dose Rate Brachytherapy and High-Dose Rate Brachytherapy], Application (External Beam Radiation Therapy [Prostate Cancer, Breast Cancer, Lung Cancer, Head and Neck Cancer, Colorectal Cancer, and Others] and Internal Beam Radiation Therapy [Prostate Cancer, Gynecological Cancer, Breast Cancer, Cervical Cancer, Penile Cancer, and Others], End-User (Hospitals, Independent Radiotherapy Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)
In the type segment of the radiotherapy/radiation oncology devices market, the gamma knife sub- category of stereotactic advanced electron/cobalt-60 linear accelerators is expected to have a significant revenue share in the year 2023. This is because of the widespread uses and various advantages of gamma knife that enhance the management of different type of chronic conditions.
Gama knife is a technique that uses numerous beams of radiation from various angles to target a specific area of the brain. Since each beam is too weak to harm the healthy tissue, it passes through on its own and is less harmful. Gamma knife also allows a powerful dose of radiation to be delivered with no or minimal damage to healthy surrounding tissue and structures and results in fewer complications such as bleeding, infection, or cerebrospinal fluid leakage. Another added advantage is that it requires no general anesthesia, eliminating the related potential side effects, and is performed in a single session, often on an outpatient basis and only occasionally requiring an overnight stay.
Moreover, several market players have a strong portfolio and key players like Leksell has a broad range of GammaKnife product offerings, some of them are Gamma Knife(R) Icon(TM), Leksell Gamma Knife(R) Lightning, Leksell Gamma Knife(R) Perfexion(TM), are now actively being involved to develop radiotherapy/radiation oncology devices.
Therefore, the widespread uses and various advantages of gamma knives enhance performance and usability, solidifying the significant impact on the growth of the overall radiotherapy/radiation oncology devices market during the forecast period from 2024 to 2030.
North America is expected to dominate the overall radiotherapy/radiation oncology devices market:
Among all the regions, North America is estimated to hold a significant revenue share in the radiotherapy/radiation oncology devices market. This can be attributed to several factors such as rising cancer cases, supportive government policies in increasing focus promoting oncology research, combined with significant advancements in product development and regulatory approvals are acting as key factors that contribute to the growth of the radiotherapy/radiation oncology devices market in the North America region during the forecast period from 2024 to 2030.
National Cancer Institute (2024) estimated that 2 million new cases of cancer will be diagnosed in the US by the end of 2024. Furthermore, it is estimated that prostate, lung, and colorectal cancers are expected to represent approximately 48% of all cancer diagnoses in men. For women, the most prevalent cancers are breast, lung, and colorectal, which are expected to account for about 51% of all new cancer diagnoses.
According to Global Cancer Observatory's data (2024), in 2022, the US represented 89.1% of all cancer cases and Canada represented 10.9% of all cancer cases in the region.
With the US expected to account for a substantial proportion of these cancer cases, healthcare providers are compelled to enhance their cancer treatment capabilities, leading to greater investment in advanced radiation therapies. This growing patient population necessitates innovative and effective treatment options, thereby expanding the market for the same.
The US Food and Drug Administration also provides a supportive environment for newer technologies to reach the market with the provision of "breakthrough device" designation to emerging technologies and products in the medical devices domain. For instance, in February 2022, GenesisCare announced that it enrolled the first patients in a trial for Boston Scientific's SpaceOAR Vue hydrogel. Boston Scientific's SpaceOAR Vue hydrogel will be evaluated in the SABRE trial, sponsored by Boston Scientific, for prostate cancer patients receiving stereotactic body radiation therapy (SBRT).
The increased emphasis on product development activities and the high interest of device manufacturers in accessing local markets further aid in the growth of the regional markets for radiotherapy/radiation oncology devices. For instance, in October 2021, the US Food and Drug Administration (FDA) granted breakthrough device designation to Alpha Tau's alpha-radiation cancer therapy to treat patients suffering from recurrent glioblastoma multiforme (GBM).
Therefore, the interplay of all the factors mentioned above would provide a conducive growth environment for the North America region in the radiotherapy/radiation oncology devices market during the forecast period from 2024 to 2030.
Radiotherapy/Radiation Oncology Devices Market key players:
Some the key market players operating in the radiotherapy/radiation oncology devices market include Siemens Healthineers AG, Elekta AB, Accuray Incorporated, BA Worldwide, BD, Isoray Inc., Mevion Medical Systems, Viewray Technologies, Inc., Eckert & Ziegler BEBIG, ZEISS, GT Medical Technologies, Inc., Hitachi, Ltd., iCAD, Inc., IntraOp Medical, Inc., Panacea Medical Technologies Pvt. Ltd., SIT - S.I.T. Sordina IORT Technologies S.p.A., Sensus Healthcare, Inc., Theragenics, Optivus Proton Therapy, Inc., P-cure, and others.
Recent Developmental Activities in the Radiotherapy/Radiation Oncology Devices Market:
Key takeaways from the Radiotherapy/Radiation Oncology Devices market report study
Target audience who can be benefited from this Radiotherapy/Radiation Oncology Devices market report study
Frequently Asked Questions for the Radiotherapy/Radiation Oncology Devices Market: